BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 27077309)

  • 1. Primaquine treatment and relapse in Plasmodium vivax malaria.
    Rishikesh K; Saravu K
    Pathog Glob Health; 2016; 110(1):1-8. PubMed ID: 27077309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report.
    He X; Pan M; Zeng W; Zou C; Pi L; Qin Y; Zhao L; Qin P; Lu Y; Baird JK; Huang Y; Cui L; Yang Z
    BMC Infect Dis; 2019 Aug; 19(1):704. PubMed ID: 31399061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria.
    Baird JK; Louisa M; Noviyanti R; Ekawati L; Elyazar I; Subekti D; Chand K; Gayatri A; Instiaty ; Soebianto S; Crenna-Darusallam C; Djoko D; Hasto BD; Meriyenes D; Wesche D; Nelwan EJ; Sutanto I; Sudoyo H; Setiabudy R
    JAMA Netw Open; 2018 Aug; 1(4):e181449. PubMed ID: 30646129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Insights into Plasmodium vivax Therapeutic Failure: CYP2D6 Activity and Time of Exposure to Malaria Modulate the Risk of Recurrence.
    Silvino ACR; Kano FS; Costa MA; Fontes CJF; Soares IS; de Brito CFA; Carvalho LH; Sousa TN
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32122891
    [No Abstract]   [Full Text] [Related]  

  • 5. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
    Rodrigo C; Rajapakse S; Fernando D
    Cochrane Database Syst Rev; 2020 Sep; 9(9):CD010458. PubMed ID: 32892362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Host Genetic Polymorphisms on the Efficacy of the Radical Cure Malaria Drug Primaquine.
    Nain M; Mohan M; Sharma A
    Am J Trop Med Hyg; 2022 Jan; 106(3):764-767. PubMed ID: 35008050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms.
    Baird JK; Battle KE; Howes RE
    Malar J; 2018 Jan; 17(1):42. PubMed ID: 29357870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radical cure for Plasmodium vivax malaria after G6PD qualitative testing in four provinces in Cambodia, results from Phase I implementation.
    Lek D; Tsai YC; Hirano J; Sovannaroth S; Bunreth V; Vonn P; Vannthen O; Bunkea T; Samphornarann T; Sokomar N; Sarath M; Kheang ST; Wong E; Burbach MK; Hughes J; Rekol H
    Malar J; 2024 Feb; 23(1):56. PubMed ID: 38395925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial.
    St Jean PL; Xue Z; Carter N; Koh GC; Duparc S; Taylor M; Beaumont C; Llanos-Cuentas A; Rueangweerayut R; Krudsood S; Green JA; Rubio JP
    Malar J; 2016 Feb; 15():97. PubMed ID: 26888075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of relapsing Plasmodium vivax malaria.
    Chu CS; White NJ
    Expert Rev Anti Infect Ther; 2016 Oct; 14(10):885-900. PubMed ID: 27530139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role of primaquine in malaria control and elimination in French-speaking Africa].
    Briolant S; Pradines B; Basco LK
    Bull Soc Pathol Exot; 2017 Aug; 110(3):198-206. PubMed ID: 28417346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function.
    Martin Ramírez A; Lombardia González C; Soler Maniega T; Gutierrez Liarte Á; Domingo García D; Lanza Suárez M; Bernal Fernández MJ; Rubio JM
    Malar J; 2020 Jul; 19(1):259. PubMed ID: 32680522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of plasmodium vivax in Northwest Frontier Province, Pakistan.
    Leslie T; Mayan I; Mohammed N; Erasmus P; Kolaczinski J; Whitty CJ; Rowland M
    PLoS One; 2008 Aug; 3(8):e2861. PubMed ID: 18682739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chloroquine-Primaquine versus Chloroquine Alone to Treat Vivax Malaria in Afghanistan: An Open Randomized Superiority Trial.
    Awab GR; Imwong M; Bancone G; Jeeyapant A; Day NPJ; White NJ; Woodrow CJ
    Am J Trop Med Hyg; 2017 Dec; 97(6):1782-1787. PubMed ID: 29141719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia.
    Thriemer K; Poespoprodjo JR; Kenangalem E; Douglas NM; Sugiarto P; Anstey NM; Simpson JA; Price RN
    PLoS Negl Trop Dis; 2020 Nov; 14(11):e0008838. PubMed ID: 33175835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea.
    Ingram RJ; Crenna-Darusallam C; Soebianto S; Noviyanti R; Baird JK
    Malar J; 2014 Dec; 13():488. PubMed ID: 25495607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-Nucleotide Polymorphisms in Glucose-6-Phosphate Dehydrogenase and their Relevance for the Deployment of Primaquine as a Radical Cure for Malaria.
    Nain M; Gill J; Mohan M; Sharma A
    Am J Trop Med Hyg; 2023 Mar; 108(3):470-476. PubMed ID: 36746659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Operational effectiveness of tafenoquine and primaquine for the prevention of Plasmodium vivax recurrence in Brazil: a retrospective observational study.
    Brito M; Rufatto R; Brito-Sousa JD; Murta F; Sampaio V; Balieiro P; Baía-Silva D; Castro V; Alves B; Alencar A; Duparc S; Grewal Daumerie P; Borghini-Fuhrer I; Jambert E; Peterka C; Edilson Lima F; Carvalho Maia L; Lucena Cruz C; Maciele B; Vasconcelos M; Machado M; Augusto Figueira E; Alcirley Balieiro A; Batista Pereira D; Lacerda M
    Lancet Infect Dis; 2024 Jun; 24(6):629-638. PubMed ID: 38452779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study.
    Devine A; Battle KE; Meagher N; Howes RE; Dini S; Gething PW; Simpson JA; Price RN; Lubell Y
    PLoS Med; 2021 Jun; 18(6):e1003614. PubMed ID: 34061843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Assessment of Chloroquine-Primaquine Combined Regimen in Adult Cohort of Plasmodium vivax Malaria from Primary Care Centres in Southwestern India.
    Saravu K; Kumar R; Ashok H; Kundapura P; Kamath V; Kamath A; Mukhopadhyay C
    PLoS One; 2016; 11(6):e0157666. PubMed ID: 27315280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.